EO2 Concepts (EO2), is an advanced wound care technology company.
Principal Investigator(s)
Botero
Funded by
EO2
Collaborating Institutions
Gonzaba Medical Group, San Antonio, TX
During a retrospective study over a period of 20 months in a wound care clinic, the efficacy of using continuous diffusion of oxygen via the TransCu O2 oxygen delivery system in the treatment of toe ulcerations was assessed. The patients in the study received continuous diffusion of oxygen therapy at rates between 3 and 10 mL/hr underneath a moisture balancing dressing, and clinicians attempted to use compression when appropriate.
EO2 Concepts (EO2), is an advanced wound care technology company.
Principal Investigator(s)
Mark Couture, DPM
Funded by
EO2
Collaborating Institutions
Central Texas Veteran’s Healthcare Administration, Temple, TX
The purpose of this project is to describe healing outcomes in the VA for the treatment of chronic ulcers using Continuous Diffusion of Oxygen therapy (CDO). CDO is a form of moist wound therapy whereby pure oxygen is added within the moist wound therapy dressing using a portable system. The system used for this study will be the TransCu O2 System, which consists of a handheld oxygen generator, a cannula for delivering the oxygen to the wound and moist wound therapy dressings. In other words, CDO is moist wound therapy with added pure oxygen supplied continuously.
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Gauduin, Marie-Claire E.
Funded by
NIH-PMS
The nature of the HIV virus has created several barriers to effective immune control by the humoral and cellular arms of adaptive immunity leading to chronic viral replication. Of the vaccine approaches tested in the SIV/macaque model, vaccination with live attenuated lentiviruses has consistently yielded the most effective and durable protection against pathogenic heterologous SIV strains. However, safety issues preclude the use of live attenuated lentiviruses in humans.